COVID-19 NEWS

Stabilitech to have oral coronavirus vaccine ready for preclinical evaluation in 3 months

UK biopharma company Stabilitech is developing OraPro-COVID-19, applying its OraPro technology with the aim of developing a viral vector with six weeks, and having a capsule ready for animal testing within 12 weeks.

N4 demonstrating utility of Nuvec^® vaccine delivery system in COVID-19 vaccines using COVID-19 DNA plasmid

N4 Pharma has initiated a proof of concept project using a Covid-19 DNA plasmid to demonstrate the utility of its Nuvec® silica nanoparticle vaccine delivery system for potential collaboration partners developing Covid-19 DNA or RNA vaccines.

Springboard offers medical device expertise to tackle COVID-19

Springboard is now offering: design reviews / risk assessments of COVID-19 related medical devices at no charge; answering ad hoc requests for advice on devices relevant to COVID-19 at no charge; device development expertise, including a willingness to tackle short term projects on a not-for profit basis; submission of services to the UK Gov call for businesses to help make NHS ventilators.

UPDATE AND NEWS FROM ONDRUGDELIVERY’S PUBLISHER IN RESPONSE TO COVID-19

The world, and our industry with it, has entered an unfamiliar and difficult period. I would like to take this opportunity to update you on how ONdrugDelivery can and will continue to provide its services uninterrupted, and tell you about some specific initiatives we're launching to help our readers, authors and clients across the global industry.

Pion Offers Its Analytical Services Pro Bono if used in the fight against COVID-19

Pion has offered its analytical services pro bono to assist in the development of vaccines and therapeutics for use in the fight against COVID-19. Its Scissor SubCutaneous Injection Site Simulator assays "simulate the stress conditions and environmental transitions of a biopharmaceutical drug when injected SC".

COVID-19, what’s left to be said and done?…well, everything!

John Cahill, Director, Senior Consultant, Quality & Compliance, PharmaLex Ireland, provides an update on the status of several COVID-19 vaccine and therapeutic development programmes, emphasising the considerable efforts being made by industry, regulatory agencies and others, to accelerate development in what is normally, due to the need for stringent regulation, a notoriously slow-moving sector.

eTheRNA launches international consortium, starts development of cross-strain protective CoV-2 mRNA vaccine

An international consortium is pooling resources to develop a nasally delivered, cross-strain protective CoV-2 mRNA vaccine. Clinical testing is scheduled for early 2021. Organisations involves include eTheRNA, EpiVax, REPROCELL, Nexelis, and CEV

Gerresheimer part of critical infrastructure, products include vital drug delivery devices

In its COVID-19 announcement, Gerresheimer has stated that it is part of the critical infrastructure of the countries in which it operates, producing vital packaging for medicines, drug delivery devices and packaging for food, beverages and hygiene and personal care products.

Catalent Responds to the Global Outbreak of COVID-19

Catalent has noted that many governments of the countries where it operates have recognised its work as essential meaning all Catalent operating facilities remain open. The company also said it was working with several customers on COVID-related antivirals, vaccines, and treatments for symptoms and effects of the disease.

With precision metal components being used in inhalers & similar devices, Advanex acknowledges critical role in supply chain

Advanex acknowledges critical role in supply chains with precision metal components being used in inhalers & similar devices, and commits to maintaining supply during turbulent period.

E3D – Elcam Drug Delivery Devices

Elcam Medical facilities Recognised by local authorities as essential, enabling continuation of production

All Elcam facilities have been recognised by the local authorities as an essential facility to enable the continuity of production. (See statement by the Israeli Ministry of Economy and Industry). Currently the company does not foresee any disruption to our operation.

Digital RDD 2020 starts April 26, replaces cancelled RDD California

For 2020, RDD is going digital. The organisers, focused on quality, have committed to providing delegates a digital conference venue open 24/7 with the following features: Digital Auditorium; Digital Platinum Sponsor Sessions; Digital Scientific Poster Session; Posters on the Digital Podium; Digital Exhibition; Digital Networking; Digital Library; Digital Personal Proceedings.

Lexaria Bioscience

Lexaria Bioscience Expands Pharma Division for development of Lipophilic Antivirals against COVID-19

Lexaria is to investigate how its patented DehydraTECH drug delivery technology could enhance delivery and effectiveness of certain antiviral drugs in the fight against coronavirus disease COVID-19. Lexaria intends to expand collaboration with leading laboratories as soon as possible.

ACG releases letter to customers in response to COVID-19

ACG has released a letter to its customers in response to the COVID-19 outbreak, and reaffirmed its commitment to providing uninterrupted supply of its products and services, and factories in all locations around the world are working at full capacity. ACG has also ensured the supply of its own raw materials for many months.

Nemera highlights obligation to provide life-saving devices to most vulnerable – including the elderly, asthmatics, diabetics

PRESS RELEASE In its COVID-19 press update, Nemera has highlighted its obligation to provide life-saving […]

The world in a state of emergency: How Sensirion helps save lives worldwide

Sensirion is lending its support to manufacturers of respiratory devices around the world to ensure their equipment is fitted with exceptionally accurate sensor technology allowing for time-resolved flow and volume measurements.

Stevanato Group

Stevanato guarantees primary packaging supplies for pharma glass containers and integrated medical device solutions

In its COVID-19 announcement, Stevanato Group has confirmed that as a major manufacturer of glass containers for pharma and a supplier of integrated solutions for medical devices is guaranteeing primary packaging supplies to support patient care worldwide.

Aptar Group Releases COVID-19 Update for its Customers and Partners

Aptar Pharma has released a message from its President and Chief Executive Officer to provide a COVID-19 update to inform its customers and partners of the measures the Group is taking in regards to the evolving coronavirus pandemic in order to continue to support our customers.

AS DEMAND SURGES, NEPHRON PREPARED TO MEET AMERICA’S NEEDS FOR RESPIRATORY MEDS

Nephron Pharmaceuticals has released a statement detailing how current demand for its medications - inhalation solutions and suspension products that treat respiratory conditions - is surging and the company is shattering sales records.

Synairgen to start trial of SNG001 in COVID-19 imminently

Synairgen has announced that it has received expedited approvals from the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients to assist with the global outbreak of the virus.

US FDA Issues Guidance for Conducting Clinical Trials during the COVID-19 pandemic.

“With this guidance issued today, the FDA is helping industry and investigators navigate the COVID-19 […]

MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic

MannKind Corporation is adjusting R&D resources that were reserved for its pipeline of investigational products for treating serious lung diseases, with the goal of prioritising work on new compounds that may have the potential to address the morbidity and mortality associated with respiratory viral infections, such as COVID-19.

PBOA Members Committed To Continuing To Reliably Manufacture Drug and Vaccine Products

PBOA reports how its member companies remain committed to serving patients by manufacturing effective, quality products for their customers, during this global health crisis, and report no material disruptions to their operations.

Insmed Provides Covid-19 Business Update

Insmed implements corporate initiatives in response to the novel coronavirus (SARS-CoV-2) global pandemic including a remote working policy to allow infectious disease specialists and pulmonologists to focus on treating patients and containing the virus. Arikares trainers will now offer remote training and onboarding for patients who initiate treatment with ARIKAYCE.

Beyond Air Submits Investigational Device Exemption to FDA for the Treatment of COVID-19

Beyond Air has submitted an IDE to the US FDA for use of its LungFit™ BRO system in the treatment of COVID-19 patients stating that a mounting body of evidence that NO is safe and well tolerated and in vitro evidence points to inhibition of viral replication in coronaviruses.

Top